PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
BackgroundThe gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
Self-citationBasu, S. K., Goldstein, J. L., Anderson, G. W., & Brown, M. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.9.3178 · Cited by 1,021
Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα
Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C., Edwards, P. A., & Tontonoz, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200367697 · Cited by 1,005 · cited 1×
“Since LXR-α has been shown to display constitutive activity in the absence of added exogenous ligand”
BackgroundSterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979 · cited 1×
“, which mediates ABCA1-promoter transcription inductio”
Chinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J.-C., Chapman, J., Najib, J., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25573 · Cited by 903
Self-citationLawn, R. M., Wade, D. P., Garvin, M. R., Wang, X., Schwartz, K., Porter, J. G., Seilhamer, J. J., Vaughan, A. M., & Oram, J. F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8119 · Cited by 724 · cited 1×
“ABCA1 is a member of the ATP-binding cassette-transporter family, which is involved in the control of apoAI-mediated cholesterol efflux from macrophage”
BackgroundScavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux
Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M. D. L. L., Phillips, M. C., Rothblat, G. H., Swaney, J. B., & Tall, A. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20982 · Cited by 694 · cited 1×
“7 ), a receptor implicated in HDL-dependent cholesterol removal from macrophage”
BackgroundMacrophages in Human Atheroma Contain PPARγ
Marx, N., Sukhova, G., Murphy, C., Libby, P., & Plutzky, J. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65540-x · Cited by 529
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118991 · Cited by 476 · cited 1×
“These data reveal a molecular mechanism that contributes to the increase in HDL-cholesterol levels observed in patients treated with fibrates and glitazones, as well as to the cardioprotective activity of these drugs in clinical studie”
BackgroundDifferential activation of adipogenesis by multiple PPAR isoforms.
Brun, R. P., Tontonoz, P., Forman, B. M., Ellis, R., Chen, J., Evans, R. M., & Spiegelman, B. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.974 · Cited by 474 · cited 1×
“15-deoxy-Δ 12-14 prostaglandin J 2 (15-d PGJ 2 ), oxidized fatty acids and the antidiabetic glitazones are ligands for PPAR-γ, which is expressed at high levels in white adipose tissue where it triggers adipocyte differentiatio”
BackgroundChinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.20.2411 · Cited by 428 · cited 1×
“In primary human macrophages, both PPAR-α and PPAR-γ activators induce the expression of the scavenger-receptor CLA-1/SR-BI, which binds high-density lipoproteins (HDL) with high affinit”
BackgroundSelf-citationEricsson, C.-G., de Faire, U., Grip, L., Svane, B., Hamsten, A., & Nilsson, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91343-4 · Cited by 426 · cited 1×
“These data reveal a molecular mechanism that contributes to the increase in HDL-cholesterol levels observed in patients treated with fibrates and glitazones, as well as to the cardioprotective activity of these drugs in clinical studie”
Background&NA; (1996) · The Endocrinologist · doi:10.1097/00019616-199609000-00019 · Cited by 417
Vu-Dac, N., Schoonjans, K., Kosykh, V, Dallongeville, J., Fruchart, J. C., Staels, B., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118118 · Cited by 397 · cited 1×
“We performed transactivation assays with the RPR-5 compound in A10 cells (a rat smooth-muscle-cell line) using full-length human PPAR-α and PPAR-γ and the pGL3-J 3 -TK reporter vecto”
MethodSelf-citationFrick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y. A., Pasternack, A., & Taskinen, M.-R. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 388
Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.-C., Laudet, V., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25713 · Cited by 297 · cited 1×
“Given the well-established, species-specific differences in the regulation of lipid and lipoprotein metabolism by PPAR-activator”
BackgroundSelf-citationForman, B. M., Ruan, B., Chen, J., Schroepfer, G. J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10588 · Cited by 280 · cited 1×
“Since LXR-α has been shown to display constitutive activity in the absence of added exogenous ligand”
BackgroundRemaley, A. T., Rust, S., Rosier, M., Knapper, C., Naudin, L., Broccardo, C., Peterson, K. M., Koch, C., Arnould, I., Prades, C., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12685 · Cited by 269 · cited 1×
“ABCA1 deficiency prevents PPAR—induced cholesterol efflux Finally, we performed efflux studies on macrophages from two Tangier patients, which lack functional ABCA1 and are defective in cholesterol efflu”
MethodSelf-citationWolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. N. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00224.x · Cited by 264 · cited 1×
“In addition, glitazone PPAR-α activators induce HDL-cholesterol, but not apoAI levels, by an unknown mechanis”
BackgroundTorra, I. P., Gervois, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199904000-00009 · Cited by 231
Self-citationInterleukin-1β Secretion Is Impaired by Inhibitors of the Atp Binding Cassette Transporter, ABC1
Hamon, Y., Luciani, M.-F., Becq, F., Verrier, B., Rubartelli, A., & Chimini, G. (1997) · Blood · doi:10.1182/blood.v90.8.2911 · Cited by 224
Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner
Delerive, P., Furman, C., Teissier, E., Fruchart, J.-C., Duriez, P., & Staels, B. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01364-8 · Cited by 199
Self-citationBarman Balfour, J. A., & Plosker, G. L. (1999) · Drugs · doi:10.2165/00003495-199957060-00007 · Cited by 198
Cross-Talk between Fatty Acid and Cholesterol Metabolism Mediated by Liver X Receptor-
Tobin, K. A. R. (2000) · Molecular Endocrinology · doi:10.1210/me.14.5.741 · Cited by 195 · cited 1×
“This is due to a direct induction of LXR-α gene transcription via PPAR-α interacting with several PPREs in the LXR-α promote”
BackgroundBecq, F., Hamon, Y., Bajetto, A., Gola, M., Verrier, B., & Chimini, G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2695 · Cited by 145
Cholesterol Metabolism and Efflux in Human THP-1 Macrophages
Kritharides, L., Christian, A. E., Stoudt, G. W., Morel, D., & Rothblat, G. H. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.10.1589 · Cited by 109 · cited 1×
“Because, in macrophages, the equilibrium between esterified and free cholesterol is not obtained even after a 24 h additional incubation perio”
BackgroundABC1: connecting yellow tonsils, neuropathy, and very low HDL
Hobbs, H. H., & Rader, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8509 · Cited by 87 · cited 1×
“Macrophages, present as foam cells in affected tissues, are the principal cell type that accumulate this excess tissue cholestero”
BackgroundThe role of apolipoprotein A-l-containing lipoproteins in atherosclerosis
Forte, T. M., & McCall, M. R. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199410000-00007 · Cited by 66
Cited by
(1998) · PubMed · Cited by 2,737
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
“Two recent studies have suggested that either PPARα (154) or PPARγ (154, 155) activation in macrophages can induce the expression of a cholesterol efflux “pump” known as ABC-A1.”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
“The solution to the paradox of PPARγ increasing lipid uptake in macrophages without increasing atherosclerotic risk has focused on the activation of lipid efflux pathways, such as reverse cholesterol transport, that prevent atherosclerotic lipid accumulation (Chawla et al., 2001a; Chinetti et al., 2001).”
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.